Doximity Inc. (NYSE: DOCS) experienced a volatile trading session on Friday, with shares climbing as much as 33% before giving back a significant portion of those gains. The stock opened at $38.86, an 88.1% jump from the prior close of $20.66, and reached an intraday high of $40.00 before closing at $27.40. Despite the substantial daily gain, the stock ended the session 31.5% below its peak, reflecting investor caution after an initial euphoric reaction.
Trading volume was exceptionally heavy, with 65.32 million shares changing hands, roughly 16.4 times the average daily volume. This suggests a high level of speculative interest and a rapid reassessment of the company's AI-driven growth prospects.
AI Adoption Drives Optimism, But Fundamentals Tell a Different Story
The surge was fueled by robust adoption of Doximity's AI-powered clinical tools. CEO Jeff Tangney highlighted that AI Search query growth exceeded 25% quarter-over-quarter, while the number of workflow active prescribers rose more than 30% year-over-year. These metrics underscore the company's successful integration of AI into healthcare workflows, a key driver of investor enthusiasm.
However, the financial results for the fiscal first quarter painted a more nuanced picture. Revenue increased 7% year-over-year to $156.6 million, but net income plummeted 54% to $24.3 million. Adjusted EBITDA declined 6% to $74.8 million, and free cash flow fell 34% to $39.6 million. Net margin contracted to 15.5% from 36.5%, while adjusted EBITDA margin slipped to 47.7% from 54.7%.
Guidance Update: Revenue Raised, Profit Outlook Trimmed
In an update to its fiscal 2027 guidance, Doximity raised its revenue midpoint by 0.9% to $676 million, with a range of $671 million to $681 million. However, the adjusted EBITDA midpoint was reduced by 3.0% to $319 million, now expected between $309 million and $329 million. For the second quarter, the company projects revenue of $170 million to $171 million.
This mixed guidance reflects the tension between AI-driven growth and margin pressures. While revenue is expected to accelerate, profitability is being squeezed by increased investment in AI capabilities and other operational costs.
Analyst Reactions Mixed
Following the earnings release and Friday's trading, several analysts updated their price targets. Piper Sandler raised its target from $42 to $47, maintaining an Overweight rating. Evercore ISI increased its target from $22 to $40, keeping an In Line rating. Raymond James lifted its target from $23 to $38, with an Outperform rating, while BMO Capital Markets moved its target from $20 to $30, maintaining a Market Perform rating.
The consensus price target among 21 analysts polled by S&P Global stands at $29.41, representing a 7.3% premium to Friday's closing price. Of those analysts, nine rate the stock as Strong Buy or Buy, eleven suggest Hold, and one issues a Sell rating.
Peer Performance and Market Context
Doximity's rally outpaced its digital-health peers. Teladoc Health (NYSE: TDOC) advanced 6.7%, while American Well Corp (NYSE: AMWL) climbed 4.6%. This outperformance suggests that investors are specifically rewarding Doximity for its AI adoption, rather than a broad sector rally.
Upcoming Economic Data and Key Risks
Investors will be watching two key economic reports next week: July's consumer price index (CPI) due Wednesday and producer price index (PPI) on Thursday, both at 08:30 EDT. These data points could influence market sentiment and interest rate expectations, potentially affecting growth stocks like Doximity.
Despite the positive AI narrative, risks remain. The company's ability to convert increased AI usage into sustainable revenue growth is unproven. Additionally, the significant decline in free cash flow reduces its financial flexibility. Should second-quarter revenue fall short of the $170 million guidance, the recent rerating could be called into question.
In summary, Doximity's stock surge reflects optimism about its AI strategy, but the underlying financials and guidance suggest that investors are pricing in a future that has yet to materialize. The coming quarters will be critical in determining whether the AI momentum translates into improved profitability.
